Tipifarnib in Treating Patients With Myeloproliferative Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005846
Recruitment Status : Unknown
Verified July 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : June 7, 2011
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

June 2, 2000
January 27, 2003
June 7, 2011
June 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00005846 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Tipifarnib in Treating Patients With Myeloproliferative Disorders
Phase I/II Study of the Farnesyltransferase Inhibitor R115777 (NSC 702818) in Patients With Myeloproliferative Disorders

RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: This phase I/II trial is studying the side effects of tipifarnib and to see how well it works in treating patents with myeloproliferative disorders.


  • Determine the toxic effects of tipifarnib in adult patients with myeloproliferative disorders.
  • Determine hematological responses, including changes in WBC count and erythroid responses, in this patient population treated with this drug.
  • Determine the cytogenetic response in bone marrow of patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to prior substantive treatment (yes vs no).

Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 4 weeks for a maximum of 4 courses in the absence of unacceptable toxicity or disease progression. Patients with continued hematologic response after completion of the fourth course may receive additional courses at the discretion of the investigator.

PROJECTED ACCRUAL: A total of 25 patients (12-13 per stratum) will be accrued for this study within 25 months.

Phase 1
Phase 2
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic/Myeloproliferative Neoplasms
Drug: tipifarnib
Not Provided
Gotlib J, Loh M, Vattikuti S, et al.: Phase I/II study of tipifarnib (ZARNESTRA, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders(MPDs): preliminary results. [Abstract] Blood 100 (Suppl 1): 798a, 2002.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided
Not Provided
Not Provided


  • Diagnosis of chronic myelogenous leukemia (CML)

    • Philadelphia chromosome (Ph) positive OR
    • BCR-ABL positive by polymerase chain reaction
    • Must meet 1 of the following 2 conditions:

      • Chronic phase

        • Persistent or progressive disease on maximum tolerated interferon or imatinib mesylate, as evidenced by increasing WBC count, peripheral blood myeloid immaturity, progressive anemia, and/or persistence or relapse of abnormal cytogenetics and/or molecular findings
        • Interferon or imatinib mesylate intolerant
      • Accelerated phase

        • Persistent or progressive disease on imatinib mesylate
      • Patients who have not received interferon or imatinib mesylate due to allergy or refusal are eligible OR
  • Diagnosis of chronic myelomonocytic leukemia

    • Proliferative type (WBC at least 12,000/mm3)
    • Less than 5% blasts in peripheral blood and no more than 20% blasts in bone marrow OR
  • Diagnosis of undifferentiated myeloproliferative disorder OR
  • Diagnosis of atypical CML (Ph negative)
  • No blast crisis phase of CML, atypical CML, or undifferentiated myeloproliferative disorders

    • No more than 20% blasts in peripheral blood or bone marrow
  • Diagnosed more than 3 months before study entry



  • 21 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • More than 4 months


  • See Disease Characteristics
  • No requirement for platelet transfusion
  • No thrombocytopenia-related bleeding


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST/ALT no greater than 2 times ULN


  • Creatinine no greater than 2.0 mg/dL


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Capable of swallowing capsules
  • No other concurrent severe disease that would preclude study compliance
  • No septicemia or other severe infection
  • No iron deficiency

    • If marrow aspirate not available, transferrin saturation at least 20% and ferritin greater than 50 ng/mL
  • No other contributing causes of anemia (e.g., autoimmune or hereditary hemolytic disorders, gastrointestinal blood loss, B12 or folate deficiency, or hypothyroidism)


Biologic therapy:

  • See Disease Characteristics
  • At least 4 weeks since prior interferon
  • At least 4 weeks since prior hematopoietic growth factors
  • No prior allogeneic bone marrow transplantation


  • At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas) except for hydroxyurea which may be used to manage elevated cell counts through the beginning of the second course of study therapy

Endocrine therapy:

  • No concurrent androgens
  • No concurrent corticosteroids (e.g., greater than 10 mg/day prednisone or equivalent steroid dosage) except as premedication for transfusions


  • Not specified


  • Not specified


  • No other concurrent standard or investigational cytotoxic agents
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Stanford University
National Cancer Institute (NCI)
Study Chair: Peter L. Greenberg, MD Stanford University
National Cancer Institute (NCI)
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP